Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $15.6900 (-7.81%) ($15.5950 - $15.6900) on Wed. Jan. 12, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.29% (three month average) | RSI | 39 | Latest Price | $15.6900(-7.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.1% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.1% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(69%) IBB(67%) ARKK(65%) IWO(62%) | Factors Impacting TGTX price | TGTX will decline at least -3.145% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-26%) UNG(-7%) USO(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.145% (StdDev 6.29%) | Hourly BBV | -2.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $18.07 | 5 Day Moving Average | $17.11(-8.3%) | 10 Day Moving Average | $18.04(-13.03%) | 20 Day Moving Average | $18.07(-13.17%) | To recent high | -55.9% | To recent low | 3.4% | Market Cap | $1.987b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |